title: A phase-ii study testing a combination chemotherapy with epirubicin and vindesine as 2nd line treatment for patients with advanced non-small-cell lung-cancer.
abstract: The European Lung Cancer Working Party conducted a phase II trial to determine the activity of a salvage regimen with high dose epirubicin (120 mg/m(2) on day 1) and vindesine (3 mg/m(2) on day 1) in patients with advanced non-small cell lung cancer failing to respond to first-line chemotherapy containing cisplatin and/or carboplatin. Courses were repeated every 3 weeks and evaluation of antitumoral response was performed after the 2 first courses. A total of 53 patients were registered, 4 were not eligible and 42 were evaluable for response. Two (5%) objective responses were documented. Although the regimen was very well tolerated, based oh the results it has to be considered inactive.
authors.affiliation: GRP MED ST REMI,REIMS,FRANCE. HOP CIVIL,CHARLEROI,BELGIUM. HOP AMBROISE PARE,MONS,BELGIUM. HOP HAYANGE,HAYANGE,FRANCE. CTR HOSP ROUBAIX,ROUBAIX,FRANCE. CTR HOSP A VESALE,MONTIGNIES TILLEUL,BELGIUM.
authors.forename: J
authors.initials: J
authors.lastname: Sculier
authors.forename: G
authors.initials: G
authors.lastname: Bureau
authors.forename: J
authors.initials: J
authors.lastname: Thiriaux
authors.forename: J
authors.initials: J
authors.lastname: Lecomte
authors.forename: P
authors.initials: P
authors.lastname: Recloux
authors.forename: M
authors.initials: M
authors.lastname: Berchier
authors.forename: F
authors.initials: F
authors.lastname: Kroll
authors.forename: D
authors.initials: D
authors.lastname: Brohee
authors.forename: P
authors.initials: P
authors.lastname: Mommen
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: R
authors.initials: R
authors.lastname: Sergysels
authors.forename: J
authors.initials: J
authors.lastname: Klastersky